Peter Holleman
28-09-2021
The complete DNA test allows for personalized treatment and so limits the chance of undesirable side effects.
Back to newsMore news
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
27-05-2021
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
Collaboration for future-proof diagnostics and to accelerate research
02-05-2023
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
Dutch House of Representatives votes for action of the Minister for arranging (provisional) reimbursement for whole genome sequencing-based DNA testing for most urgent groups of cancer patients
25-02-2021
On February 25 2021, the Dutch House of Representatives adopted a motion approving reimbursement on a provisional basis of a …
I know how important knowledge of hereditary predisposition to cancer can be. This is why I think it is so important that comprehensive patient reports include precisely that carrier information, if the patient wishes to be informed of it.
Member of the Patient Board